Rina Takamiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rina Takamiya has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Motoko Takahashi
Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo, Japan
3 shared publications - Shigeru Ariki
Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo, Japan
3 shared publications Yoshihiro Hasegawa
Department of Biochemistry, Sapporo Medical University, School of Medicine, Hokkaido, Japan
3 shared publicationsYoshio Kuroki
Department of Biochemistry, Sapporo Medical University, School of Medicine, Hokkaido, Japan
3 shared publications- Atsushi Saito
Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan
2 shared publications Jiro Hashimoto
Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo 060-8556, Japan
2 shared publications
Latest Publications
- 28 April 2022
- Published by Wiley in The FASEB Journal
- Vol. 36 (5) , e22301
Group IVE cytosolic phospholipase A 2 limits psoriatic inflammation by mobilizing the anti‐inflammatory lipid N ‐acylethanolamine
Psoriasis is an inflammatory disorder characterized by keratinocyte hyper‐proliferation and Th17‐type immune responses. However, the roles of bioactive lipids and the regulation of their biosynthesis in this chronic skin disease are not fully understood. Herein, we show that group IVE cytosolic phospholipase A 2 (cPLA 2 ε/PLA2G4E) plays a counterregulatory role against psoriatic inflammation by producing the anti‐inflammatory lipid N ‐acylethanolamine (NAE). Lipidomics analysis of mouse skin revealed that NAE species and their precursors ( N ‐acyl‐phosphatidylethanolamine and glycerophospho‐ N ‐acylethanolamine) were robustly increased in parallel with the ongoing process of imiquimod (IMQ)‐induced psoriasis, accompanied by a marked upregulation of cPLA 2 ε in epidermal keratinocytes. Genetic deletion of cPLA 2 ε exacerbated IMQ‐induced ear swelling and psoriatic marker expression, with a dramatic reduction of NAE‐related lipids in IMQ‐treated, and even normal, skin. Stimulation of cultured human keratinocytes with psoriatic cytokines concomitantly increased PLA2G4E expression and NAE production, and supplementation with NAEs significantly attenuated the cytokine‐induced upregulation of the psoriatic marker S100A9 . Increased expression of cPLA 2 ε was also evident in the epidermis of psoriatic patients. These findings reveal for the first time the in vivo role of cPLA 2 ε, which is highly induced in the keratinocytes of the psoriatic skin, promotes the biosynthesis of NAE‐related lipids, and contributes to limiting psoriatic inflammation.
- 28 April 2022
- Published by Wiley in The FASEB Journal
- Vol. 36 (5) , e22301
Group IVE cytosolic phospholipase A 2 limits psoriatic inflammation by mobilizing the anti‐inflammatory lipid N ‐acylethanolamine
Psoriasis is an inflammatory disorder characterized by keratinocyte hyper‐proliferation and Th17‐type immune responses. However, the roles of bioactive lipids and the regulation of their biosynthesis in this chronic skin disease are not fully understood. Herein, we show that group IVE cytosolic phospholipase A 2 (cPLA 2 ε/PLA2G4E) plays a counterregulatory role against psoriatic inflammation by producing the anti‐inflammatory lipid N ‐acylethanolamine (NAE). Lipidomics analysis of mouse skin revealed that NAE species and their precursors ( N ‐acyl‐phosphatidylethanolamine and glycerophospho‐ N ‐acylethanolamine) were robustly increased in parallel with the ongoing process of imiquimod (IMQ)‐induced psoriasis, accompanied by a marked upregulation of cPLA 2 ε in epidermal keratinocytes. Genetic deletion of cPLA 2 ε exacerbated IMQ‐induced ear swelling and psoriatic marker expression, with a dramatic reduction of NAE‐related lipids in IMQ‐treated, and even normal, skin. Stimulation of cultured human keratinocytes with psoriatic cytokines concomitantly increased PLA2G4E expression and NAE production, and supplementation with NAEs significantly attenuated the cytokine‐induced upregulation of the psoriatic marker S100A9 . Increased expression of cPLA 2 ε was also evident in the epidermis of psoriatic patients. These findings reveal for the first time the in vivo role of cPLA 2 ε, which is highly induced in the keratinocytes of the psoriatic skin, promotes the biosynthesis of NAE‐related lipids, and contributes to limiting psoriatic inflammation.
- Open Access
- 16 August 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-13
Disruption of the structural and functional features of surfactant protein A by acrolein in cigarette smoke
The extent to which defective innate immune responses contribute to chronic obstructive pulmonary disease (COPD) is not fully understood. Pulmonary surfactant protein A (SP-A) plays an important role in regulating innate immunity in the lungs. In this study, we hypothesised that cigarette smoke (CS) and its component acrolein might influence pulmonary innate immunity by affecting the function of SP-A. Indeed, acrolein-modified SP-A was detected in the lungs of mice exposed to CS for 1 week. To further confirm this finding, recombinant human SP-A (hSP-A) was incubated with CS extract (CSE) or acrolein and then analysed by western blotting and nanoscale liquid chromatography-matrix-assisted laser desorption/ionisation time-of-flight tandem mass spectrometry. These analyses revealed that CSE and acrolein induced hSP-A oligomerisation and that acrolein induced the modification of six residues in hSP-A: His39, His116, Cys155, Lys180, Lys221, and Cys224. These modifications had significant effects on the innate immune functions of hSP-A. CSE- or acrolein-induced modification of hSP-A significantly decreased hSP-A’s ability to inhibit bacterial growth and to enhance macrophage phagocytosis. These findings suggest that CS-induced structural and functional defects in SP-A contribute to the dysfunctional innate immune responses observed in the lung during cigarette smoking.
- 16 August 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-13
Open AccessDisruption of the structural and functional features of surfactant protein A by acrolein in cigarette smoke
The extent to which defective innate immune responses contribute to chronic obstructive pulmonary disease (COPD) is not fully understood. Pulmonary surfactant protein A (SP-A) plays an important role in regulating innate immunity in the lungs. In this study, we hypothesised that cigarette smoke (CS) and its component acrolein might influence pulmonary innate immunity by affecting the function of SP-A. Indeed, acrolein-modified SP-A was detected in the lungs of mice exposed to CS for 1 week. To further confirm this finding, recombinant human SP-A (hSP-A) was incubated with CS extract (CSE) or acrolein and then analysed by western blotting and nanoscale liquid chromatography-matrix-assisted laser desorption/ionisation time-of-flight tandem mass spectrometry. These analyses revealed that CSE and acrolein induced hSP-A oligomerisation and that acrolein induced the modification of six residues in hSP-A: His39, His116, Cys155, Lys180, Lys221, and Cys224. These modifications had significant effects on the innate immune functions of hSP-A. CSE- or acrolein-induced modification of hSP-A significantly decreased hSP-A’s ability to inhibit bacterial growth and to enhance macrophage phagocytosis. These findings suggest that CS-induced structural and functional defects in SP-A contribute to the dysfunctional innate immune responses observed in the lung during cigarette smoking.
- Open Access
- 1 April 2017
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 198 (7) , 2898-2905
Surfactant Protein A Inhibits Growth and Adherence of Uropathogenic Escherichia coli To Protect the Bladder from Infection
Surfactant protein A (SP-A) is a multifunctional host defense collectin that was first identified as a component of pulmonary surfactant. Although SP-A is also expressed in various tissues, including the urinary tract, its innate immune functions in nonpulmonary tissues are poorly understood. In this study, we demonstrated that adherence of uropathogenic Escherichia coli (UPEC) to the bladder was enhanced in SP-A–deficient mice, which suggests that SP-A plays an important role in innate immunity against UPEC. To understand the innate immune functions of SP-A in detail, we performed in vitro experiments. SP-A directly bound to UPEC in a Ca2+-dependent manner, but it did not agglutinate UPEC. Our results suggest that a bouquet-like arrangement seems unsuitable to agglutinate UPEC. Meanwhile, SP-A inhibited growth of UPEC in human urine. Furthermore, the binding of SP-A to UPEC decreased the adherence of bacteria to urothelial cells. These results indicate that direct action of SP-A on UPEC is important in host defense against UPEC. Additionally, adhesion of UPEC to urothelial cells was decreased when the cells were preincubated with SP-A. Adhesion of UPEC to urothelial cells is achieved via interaction between FimH, an adhesin located at bacterial pili, and uroplakin Ia, a glycoprotein expressed on the urothelium. SP-A directly bound to uroplakin Ia and competed with FimH for uroplakin Ia binding. These results lead us to conclude that SP-A plays important roles in host defense against UPEC.
- 1 April 2017
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 198 (7) , 2898-2905
Open AccessSurfactant Protein A Inhibits Growth and Adherence of Uropathogenic Escherichia coli To Protect the Bladder from Infection
Surfactant protein A (SP-A) is a multifunctional host defense collectin that was first identified as a component of pulmonary surfactant. Although SP-A is also expressed in various tissues, including the urinary tract, its innate immune functions in nonpulmonary tissues are poorly understood. In this study, we demonstrated that adherence of uropathogenic Escherichia coli (UPEC) to the bladder was enhanced in SP-A–deficient mice, which suggests that SP-A plays an important role in innate immunity against UPEC. To understand the innate immune functions of SP-A in detail, we performed in vitro experiments. SP-A directly bound to UPEC in a Ca2+-dependent manner, but it did not agglutinate UPEC. Our results suggest that a bouquet-like arrangement seems unsuitable to agglutinate UPEC. Meanwhile, SP-A inhibited growth of UPEC in human urine. Furthermore, the binding of SP-A to UPEC decreased the adherence of bacteria to urothelial cells. These results indicate that direct action of SP-A on UPEC is important in host defense against UPEC. Additionally, adhesion of UPEC to urothelial cells was decreased when the cells were preincubated with SP-A. Adhesion of UPEC to urothelial cells is achieved via interaction between FimH, an adhesin located at bacterial pili, and uroplakin Ia, a glycoprotein expressed on the urothelium. SP-A directly bound to uroplakin Ia and competed with FimH for uroplakin Ia binding. These results lead us to conclude that SP-A plays important roles in host defense against UPEC.
- 1 November 2014
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 454 (3) , 364-368
The single N-glycan deletion mutant of soluble ErbB3 protein attenuates heregulin β1-induced tumor progression by blocking of the HIF-1 and Nrf2 pathway
- 1 November 2014
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 454 (3) , 364-368
The single N-glycan deletion mutant of soluble ErbB3 protein attenuates heregulin β1-induced tumor progression by blocking of the HIF-1 and Nrf2 pathway